

## **NeuroVista Corporation**

NeuroVista Corporation is developing an implantable Seizure Advisory System (SAS) for people with medically intractable epilepsy. The SAS employs implanted electrodes, data acquisition capability, and digital signal processing techniques in order to acquire and process real-time intracranial EEG (iEEG) data. This data is then used to tailor an algorithm for the patient that determines the likelihood of seizure over time. Seizure advisory indicators are then used to communicate the results of the algorithmic analysis to the patient on a real time basis. The iEEG properties used for algorithm development have been identified from the world's largest human iEEG data base, developed by NeuroVista.

The SAS includes an Implantable Lead Assembly (ILA) which is implanted subdurally and provides the iEEG interface to the patient's cerebral cortex. The iEEG signals are received by an implantable telemetry unit (ITU) implanted in a sub-clavicular pocket. The ITU transmits the data wirelessly out of the patient's body to a Personal Advisory Device (PAD). The PAD is a pager-like device carried externally by the patient that receives continuous iEEG data from the ITU and processes the data in real time with a seizure advisory algorithm tailored to the patient. The PAD provides continuous communication of seizure likelihood to the patient through a series of three advisory indicators corresponding to low, moderate, or high likelihood of seizure. The PAD also stores iEEG and advisory data on data cards for subsequent retrieval and analysis. Long-term studies in canines with spontaneous epilepsy have confirmed the system's ability to collect continuous high quality iEEG and to identify seizures with high sensitivity and specificity.

The NeuroVista SAS is a disruptive technology with the potential to change the practice of epileptology. The SAS will provide information that will allow people with intractable epilepsy to avoid the risk and anxiety associated with unwarned seizures, prevent impending seizures from occurring with known acute anti-seizure interventions, and allow them to live more normally between seizures.

NeuroVista has pursued strong patent protection of our technology and has obtained 16 issued patents, 38 published pending patent applications, and additional unpublished pending patent applications addressing seizure prediction and other aspects of our technology.

The key development challenges are to complete the approval process for a multi-center feasibility clinical study and to demonstrate safety and algorithm performance in patients with intractable epilepsy that translates to improved quality of life and seizure reduction.

The company's key milestone/timeline is to initiate a multi-center feasibility clinical study in Q2 2010.

We are seeking additional funds to complete our multi-center feasibility clinical study and to expand our clinical program to support commercialization.